First evidence of PSMA expression in differentiated thyroid cancer using [68Ga]PSMA-HBED-CC PET/CT

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 42, Issue 10, 2015, Pages 1622-1623

  Verburg, Frederik A ^a,b   Krohn, Thomas ^a   Heinzel, Alexander ^a   Mottaghy, Felix M ^a,b   Behrendt, Florian F ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC MEMBRANE ANTIGEN; PSMA HBED CC GA 68; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; EDETIC ACID; GALLIUM; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II, HUMAN; MEMBRANE ANTIGEN; N,N'-BIS(2-HYDROXY-5-(ETHYLENE-BETA-CARBOXY)BENZYL)ETHYLENEDIAMINE N,N'-DIACETIC ACID; TUMOR MARKER;

ARTICLE; CANCER STAGING; CERVICAL LYMPH NODE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIFFERENTIATED THYROID CANCER; HUMAN; LUNG METASTASIS; LYMPH NODE METASTASIS; PROTEIN EXPRESSION; RADIOISOTOPE THERAPY; ANALOGS AND DERIVATIVES; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; EVIDENCE BASED MEDICINE; METABOLISM; MOLECULAR IMAGING; MULTIMODAL IMAGING; PILOT STUDY; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; THYROID NEOPLASMS;

ANTIGENS, SURFACE; BIOMARKERS, TUMOR; EDETIC ACID; EVIDENCE-BASED MEDICINE; GALLIUM RADIOISOTOPES; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; MOLECULAR IMAGING; MULTIMODAL IMAGING; PILOT PROJECTS; POSITRON-EMISSION TOMOGRAPHY; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; THYROID NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84938417428     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-015-3065-y     Document Type: Article

References (5)

1. Afshar-Oromieh A, Avtzi E, Giesel FL, Holland-Letz T, Linhart HG, Eder M, et al. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2015;42:197–209.
2. Kratochwil C, Giesel FL, Eder M, Afshar-Oromieh A, Benešová M, Mier W, Kopka K, Haberkorn U. [(177)Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer. Eur J Nucl Med Mol Imaging 2015;42:987–8.
3. Chang SS, Reuter VE, Heston WD, Bander NH, Grauer LS, Gaudin PB. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 1999;59:3192–8.
4. Demirci E, Ocak M, Kabasakal L, Decristoforo C, Talat Z, Halaç M, et al. (68)Ga-PSMA PET/CT imaging of metastatic clear cell renal cell carcinoma. Eur J Nucl Med Mol Imaging 2014;41:1461–2.
5. Luster M, Weber T, Verburg FA. Differentiated thyroid cancer-personalized therapies to prevent overtreatment. Nat Rev Endocrinol 2014;10:563–74.